MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - March 15, 2012) -
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
that a
HuCAL antibody generated by its division for research and diagnostic
antibodies,
AbD Serotec, has been included in a clinical diagnostic test in the
area of
maternal health screening by a major diagnostic supplier. The product
is CE
marked and available within the EU and non-regulated countries. AbD
Serotec
receives royalties on product sales and will continuously supply the
customer
with recombinant antibody material.
"Today's news further increases the number of clinical diagnostic kits
relying
on a HuCAL antibody as an essential component," commented Dieter Feger,
Head of
AbD Serotec. "The market entry of yet another test system including a
HuCAL
antibody is a further significant step forward for our recombinant
technology in
the field of in vitro diagnostics. AbD Serotec is committed to continue
driving
this process as we believe the HuCAL technology enables the
generation of
superior diagnostics reagents."
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in
the pharmaceutical industry. By successfully applying this and other
patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
The
company'sAbD Serotec unit uses HuCAL and other antibody technologies to
generate
superior monoclonal antibodies for research and diagnostic applications.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipeline of more than 70 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just
a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow.
MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
For
regular updates about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®,
CysDisplay®, RapMAT® and
arYla® are registered trademarks of MorphoSys. Ylanthia® and
100 billion
high potentials™ are trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology
GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
concerning the
MorphoSys group of companies. The forward-looking statements contained
herein
represent the judgment of MorphoSys as of the date of this release and
involve
risks and uncertainties. Should actual conditions differ from the
Company's
assumptions, actual results and actions may differ from those
anticipated.
MorphoSys does not intend to update any of these forward-looking
statements as
far as the wording of the relevant press release is concerned.
Media Release:
http://hugin.info/130295/R/1593988/501690.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1593988]
